Stock Taper
SCREENER COMPARE ANY 2 STOCKS
LPCN
LIPOCINE INC.
NASDAQ
$2.17
▼ DOWN 2.69% (-0.06)

KEY STATISTICS

Market Cap$17.89 M
52w High$12.37
52w Low$1.81
Dividend Yield—
Frequency—
P/E-1.21
Volume19.55K
Shares Out.8.24M

COMPANY

LEADERSHIP

Mahesh V. Patel
CHIEF EXECUTIVE
Mahesh V. Patel

COMPENSATION 2026

Salary$584,775
Stock Awards$0
Incentive Plan Pay$292,388
All Other Comp.$19,751
Total$986,336

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 22, 2013
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
14

PRICE TARGET

Target High$6.00
Target Low$6.00
Target Median$6.00
Target Consensus$6.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$219.00K
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2023-05-12Reverse1:17

PRICE

$2.17 ▼ DOWN 2.69% (−$0.06)
OVERLAYS
$2.12$2.16$2.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.17

About Lipocine Inc.

https://www.lipocine.com ↗

Lipocine Inc. is a clinical-stage biopharmaceutical company developing oral therapies for neuroendocrine and metabolic disorders, with lead products like TLANDO and multiple pipeline candidates in various clinical trial phases.

INDUSTRY

Biotechnology

A PRODUCT LIPOCINE INC. IS KNOWN FOR

LPCN 1154
LPCN 1154

LPCN 1154 is Lipocine’s investigational oral treatment for postpartum depression, recently completing Phase 3 trials, marking a strategic focus on developing CNS disorder therapies.

COMPETITORS

COMPETITOR
BIIB COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q2-2025Q3-2025
License— $500K $500K
Reportable Segment$93.86K — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
16
LISTED HERE
2
RANKED BY POSITION SIZE
VTS.AX
0.00% · 142.8K
DFAS
0.00% · 6.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
49.65%
HOLDERS
57
TOP 12 OF 57 · RANKED BY POSITION SIZE
Vhcp Management, LLC
849.9K sh · $3.13M
Blackrock Fund Advisors
538.1K sh · $1.98M
Ikarian Capital, LLC
508.6K sh · $4.06M
Blackrock Institutional Trust Company, N.A.
365.9K sh · $1.35M
Del Mar Asset Management, LP
330.7K sh · $2.02M
Eversept Partners, LP
295.0K sh · $2.36M
Diadema Partners LP
260.9K sh · $2.1M
Vanguard Group Inc
221.9K sh · $1.78M
Rosalind Advisors, Inc.
221.6K sh · $1.77M
Aigh Capital Management LLC
200.0K sh · $1.6M
Stempoint Capital LP
160.4K sh · $1.28M
Boothbay Fund Management, LLC
140.5K sh · $1.12M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR:
Grissinger Michael
— · —
2026-08-03
★
DIRECTOR
Grissinger Michael
Purchase · 2.0K shares
2026-08-03
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Patel Mahesh V.
Purchase · 52.8K shares
2026-06-29
★
DIRECTOR
Jene Jill M.
Purchase · 1.8K shares
2026-06-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. NEUTRAL

SECTORS PEERS

PEERPRICE
ANL$13.82COMPARE
EDSA$4.62COMPARE
PMN$13.79COMPARE
BLRX$2.60COMPARE
LNAI$2.37COMPARE
GOVX$0.72COMPARE
OSRH$0.12COMPARE
MBRX$0.65COMPARE